Misoprostol is already produced in the public system of Río Negro, Santa Fe and San Luis.
The National Administration of Drugs, Food and Medical Technology (Anmat) authorized the marketing of mifepristonethe medicine that along with misoprostol It is the most efficient procedure recommended by the World Health Organization (WHO) for voluntary interruptions of pregnancy (IVE)so from now on its distribution and sale in pharmacies and its use in the public health system, social works and prepaid are allowed.
The decision was made official by the provision 1470/2023 and is framed in compliance with the Ley 27.610 of access to the voluntary and legal interruption of pregnancy (IVE/ILE), reported the Ministry of Health through a statement.
Anmat authorized Laboratorio Domínguez to produce and market the pill.
Until now, combined treatment was guaranteed by the public health system, which bought mifepristone abroad, as there was no domestic production.
Mifepristone “is a highly effective medication according to the WHO for access to the termination of pregnancy.”
The private company thus achieves official authorization, while the Santa Fe Industrial Pharmaceutical Laboratory (LIF) is in the process of developing the public production of mifepristone and in 2022 the Ministry of Health of the province of Buenos Aires signed an agreement with the National University of La Plata for its production.
Mifepristone “is a highly effective medication according to the WHO for access to pregnancy termination,” explained Valeria Isla, national director of Sexual and Reproductive Health in a note made with Télam earlier this year.
“The combination of both tablets is 97% effective for performing an IVE with medication,” he added.
The Ministry of Health of the Nation began, in 2022, the distribution of the combined treatment of mifepristone and misoprostol, through the Remediar program, to the provincial sexual and reproductive health programs and health centers and public hospitals that guarantee IVE/ILE in all the country.
Misoprostol is already produced in the public system of Río Negro, Santa Fe and San Luis.
#Mifepristona
There will be production in the country of Mifepristone!!!! This will enable access to combined treatment to terminate pregnancies in a safe, effective and quality manner.
💚💪🏻🌈 pic.twitter.com/flhN8UbsQ3— National Campaign for the Right to Abortion- CABA 💚 (@CampAbortoCABA) March 8, 2023
Mifepristone has been on the WHO list of essential medicines since 2005 and, together with misoprostol, forms the “most effective and safest regimen for medical abortion,” the agency highlights on its official website.
With the provision of the Anmat regarding mifepristone, “the basic regulatory package necessary to ensure the availability of the best care and clinical standards in all health providers in the country, both public, social works or prepaid, is completed as recommended in the Protocol for the comprehensive care of people with the right to voluntary and legal termination of pregnancy,” said the portfolio led by Carla Vizzotti.
Vizzotti: “Statistics show that between 2020 and 2021 a 40% drop in maternal mortality from pregnancy ending in abortion was achieved.”
And he added that “statistics show that between 2020 and 2021 a 40% decrease in maternal mortality from pregnancy ended in abortion was achieved. Maternal deaths linked to ‘medical abortion, other abortion, unspecified abortion and failed attempt of abortion’ fell from 13 in 2020 to 9 in 2021. If all deaths from abortion are considered, it can be seen that the decrease was from 23 in 2020 to 15 in 2021”.
This year, the United States Food and Drug Administration (FDA) authorized pharmacies in that country to sell mifepristone that was only available in doctors’ offices, clinics, and online pharmacies.
It was a decision that came after the US Court of Justice annulled the Roe v. Wade ruling that considered the right to abortion constitutional.
After that ruling, several states restricted access to the right, and some even prohibited it.
